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Intracellular antibodies have become powerful tools for imag-
ing, modulating and neutralizing endogenous target proteins. 
Here, we describe an optogenetically activated intracellu-
lar antibody (optobody) consisting of split antibody frag-
ments and blue-light inducible heterodimerization domains. 
We expanded this optobody platform by generating several 
optobodies from previously developed intracellular anti-
bodies, and demonstrated that photoactivation of gelsolin 
and β2-adrenergic receptor (β2AR) optobodies suppressed 
endogenous gelsolin activity and β2AR signaling, respectively.
Intracellular antibodies (intrabodies) have attracted interest for 
their ability to manipulate endogenous protein function1,2. Notably, 
small antibody fragments, such as single-domain antibodies (VHH, 
known as nanobodies) and single-chain variable fragments (scFv), 
have been widely used as efficient tools to define the function of 
endogenous proteins and determine their roles in signaling path-
ways3. Despite the widespread use of intrabodies, no techniques 
for directly controlling intrabody activity in living cells have been 
reported. The current methods for inducing intrabody activity 
in cells rely on chemically induced intrabody expression4 or deg-
radation5. However, these methods do not allow for fine-tuned 
regulation of intrabody activity, limiting the use of intrabodies in 
dissecting complex signaling networks. Direct modulation of pro-
tein activity with an optogenetic tool adds further precision in terms 
of spatial and temporal regulation of proteins6.
Here, we present an optogenetic platform for inducing activa-
tion of intrabodies that allows the function of endogenous target 
proteins to be precisely controlled in living cells. We combined a 
split-protein system and light-responsive proteins to generate an 
optogenetically activatable intracellular antibody (optobody).
To develop an optobody platform, we first identified the best-
suited split site on opposite sides of complementarity-determining 
regions (CDRs) in a green fluorescent protein (GFP) nanobody7, by 
conjugating each split GFP nanobody fragment to a FK506 bind-
ing protein fused to FKBP rapamycin binding protein (FKBP–FRB) 
(Fig. 1a and Supplementary Fig. 1a,b). The efficiency of each split 
site was measured by assessing the association of the correspond-
ing split GFP nanobody with Mito-GFP (Supplementary Fig. 1c). 
We found that the split sites, which divide CDR1/2 and CDR3, pro-
duced clear accumulation of GFP nanobody fragments with Mito-
GFP after rapamycin treatment, and that the N65/C66 split site was 
more efficient in rapamycin-mediated targeting of GFP (Fig. 1b and 
Supplementary Fig. 1d,e). The affinity of activated GFP nanobody 
N65/C66 fragments to GFP was analyzed by biolayer interferometry 
(BLI), which yielded an estimated affinity constant (KD) value of 
7.27 × 10−8 M, an affinity as high as that for the intact GFP nano-
body (Fig. 1c,d and Supplementary Fig. 2). Therefore, the GFP 
nanobody fragments N65 and C66 were used in subsequent experi-
ments. Although not the focus of this work, the chemogenetically 
activatable intracellular antibody (chemobody) may offer advan-
tages for in vivo applications.
To create an optobody platform, we linked the GFP nanobody 
fragments N65 and C66 to the Magnet optical dimerization tools 
nMagHigh1 and pMagHigh1 (ref. 8), respectively. The GFP nano-
body N65-nMagHigh1 was paired with two different orienta-
tions of pMagHigh1 and GFP nanobody C66: pMagHigh1-C66 
and C66-pMagHigh1 (Supplementary Fig. 3a). N65-nMagHigh1 
paired with pMagHigh1-C66 showed efficient targeting to Mito-
GFP in response to light stimulation (Supplementary Fig. 3b,c). 
Co-immunoprecipitation experiments supported the low back-
ground of the inactive GFP optobody in darkness and the 
light-induced capture of GFP by the activated GFP optobody 
(Supplementary Fig. 4). These results establish the N65/C66 split 
site and the indicated configuration of the Magnet fragments as the 
optimal optobody platform (Fig. 1e).
Separate GFP optobody fragments were accumulated at Mito-
GFP immediately after light stimulation, reaching saturation after 
about 1 h (Fig. 1f,g, Supplementary Fig. 12a and Supplementary 
Video 1). The GFP optobody can specifically target GFP within 
the nucleus, at the plasma membrane, and on the cytoplasmic 
face of the Golgi apparatus (Supplementary Fig. 5a). The local 
stimulation in individual cells effectively activated the GFP opto-
body with high spatial resolution (Supplementary Fig. 5b and 
Supplementary Video 2). By varying the power density or dura-
tion of light input, we showed that a single pulse of light power 
greater than 100 μW mm−2 efficiently turned on the GFP optobody, 
whereas increasing the duration of light input at modest power den-
sity (50 μW mm−2) induced higher-amplitude activation of the GFP 
optobody (Supplementary Fig. 5c,d).
The variable domain of the antibody contains a conserved disul-
fide bond that provides intrinsic stability9. The design of the opto-
body separates two cysteine residues (Cys24 and Cys94 on the GFP 
nanobody) from each other on the fragments before activation. A 
C24S mutant GFP optobody interacted less efficiently with Mito-
GFP than the wild-type GFP optobody (Supplementary Fig. 6). 
This indicates that the interaction between two Cys residues may 
help activate and stabilize the optobody and restrict its flexibility for 
target binding.
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To explore whether the optobody platform could be com-
bined with other blue-light mediated photoreceptors, we replaced 
pMagHigh1 with pMag or pMagFast1 (ref. 8) and generated a GFP 
optobody using iLID and SspB R73Q10. Contrary to our expecta-
tions, pMag- and pMagFast1-conjugated GFP optobodies are less 
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Fig. 1 | Optobody design and development. a, Schematic representation of the secondary structure of a GFP nanobody and its split sites (indicated by 
green arrowheads). b, Three pairs of split GFP nanobodies fused to FRB and FKBP. Pearson’s correlation for each split GFP nanobody with Mito-GFP in 
HeLa cells 4 h after addition of 500 nM rapamycin (rap; n ≥ 8 for each group). ***P < 0.005 by Student’s two-tailed t-test. c, Binding of inactive or activated 
GFP nanobody fragments 3 mg ml−1 of His6-tagged GFP bound Ni-NTA probe on a BLItz system. Red dotted lines mark the start of binding (left) and 
dissociation (right) phases. d, Table showing the calculated kinetics parameters. e, Schematic depiction of blue-light induced activation of an optobody.  
f, Fluorescence images of HeLa cells expressing a GFP optobody N-terminal fragment, GFP optobody C-terminal fragment and Mito-GFP, before and 1 h 
after illumination with 488-nm light every 2 min. Scale bars, 10 μm. g, Pearson’s correlation for each GFP optobody fragment with Mito-GFP in HeLa cells, 
tested as in f. Correlations were calculated for single cells (n = 27). Values are means ± s.e.m. Detailed statistical information is provided in the Methods.
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fused to iLID and SspB R73Q was optogenetically activated as 
efficiently as nMagHigh1 and pMagHigh1 fused to the GFP opto-
body (Supplementary Fig. 7). These results suggest that optoge-
netic modules with a dimerization affinity comparable to that of 
nMagHigh1-pMagHigh1 or iLID-SspB R73Q are capable of form-
ing an operational optobody.
Through switching off the light on the cells activating GFP 
optobody, we found no dissociation of GFP optobody from 


















































































































































































































Fig. 2 | applications of optobodies for inducible protein targeting and manipulation. a–c, Fluorescence images showing light-dependent operation of an 
actin optobody (a), β2AR optobody (b) and GSN optobody-Mito (c). Cells were stimulated with 488-nm (blue) light every 2 min for 1 h. Lower panels are 
optobody intensity profiles along the yellow and red lines in the upper images. d, Schematic depiction of an optobody derived from scFv. e, Images of HeLa 
cells expressing split-scFvGCN4 fragments (based on a split site in the VH domain) and Mito-EGFP-24xGCN4 peptide. Cells were illuminated every 2 min 
for 1 h. f, Intensity profile of a GCN4 optobody along the yellow lines on images e. g, Pearson’s correlation for each GCN4 optobody fragment targeting 
the Mito-EGFP-24xGCN4 peptide following blue-light stimulation, obtained every 2 min (n = 10). Values are means ± s.e.m. Scale bars, 10 μm. Detailed 
statistical information is provided in the Methods.
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mitochondria-conjugated GFP (Supplementary Fig. 7e and 
Supplementary Video 3). To investigate how the activated GFP 
optobody maintains stable targeting of GFP even in darkness, we 
monitored detachment of the C-terminal fragment from the mito-
conjugated N-terminal fragment in the absence or presence of GFP. 


























































































































































































Fig. 3 | Optogenetic inhibition of endogenous GsN activity and β2ar signaling with a GsN optobody and β2ar optobody, respectively. a, Tracking the 
migration of a group of NIH3T3 cells expressing a GSN optobody, with and without light stimulation. Each line represents the migration path of one cell 
(n = 50), monitored every 3 min for 5 h with simultaneous blue-light illumination. b,c, Quantification of migration distance (b) and instantaneous speed 
(c) of NIH3T3 cells expressing FuRed, GSN nanobody and GSN optobody, and stimulated with light. Instantaneous speed at 0 h (−Light) and 2 h (+Light) 
points in b were measured (n ≥ 132 for each group). d, Representative images of HEK293 cells expressing a β2AR optobody and β2AR-iRFP. Cells were 
illuminated with blue light every 3 min for 8 h and then treated with 1 μM ISO for 1 h. e,f, Quantification of β2AR-iRFP internalization in HEK293 cells 
expressing FuRed, β2AR nanobody or β2AR optobody, with or without light stimulation, 1 h after addition of 1 μM ISO addition (n ≥ 23 for each group).  
g, Pseudocolor images of R-GECO and fluorescence images of β2AR optobody and Cnga2 (C460W, E583M)-mEGFP in HEK293 cells. Cells were 
illuminated as in d and treated with 1 μM ISO. h, Relative intensity of R-GECO before and after addition of 1 μM ISO in HEK293 cells expressing iRFP, β2AR 
nanobody or β2AR optobody with or without light stimulation (n ≥ 50 for each group). Scale bars, 10 μm. Values are means ± s.e.m. NS, not significant, 
***P < 0.005 by Student’s two-tailed t-test. Detailed statistical information is provided in the Methods.
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dissociated in the absence of GFP, but this dissociation was blocked 
by the presence of GFP. These results demonstrate that optobody 
activation is irreversible because of the high-affinity binding of the 
GFP optobody to GFP.
We next sought to convert the deGraFP11 to a photo-inducible 
system; we replaced the NSlmb-GFP nanobody with NSlmb-GFP 
optobody. Following light-induced activation of the NSlmb-GFP 
optobody, EGFP-H2B intensity started to decrease, ultimately 
reaching a level comparable to that of the NSlmb-GFP nanobody 
(Supplementary Fig. 9). These results indicate the broad applicabil-
ity of the optobody, showing that it simply converts a conventional 
method into a light-inducible system.
We also developed a mCherry optobody from a mCherry nano-
body12. The mCherry optobody fragments showed no background 
of binding to Mito-mCherry in darkness, and were dramatically 
activated by blue-light stimulation, as shown for the GFP optobody 
(Supplementary Fig. 10). A mCherry optobody will be helpful for 
users with concerns about cross-talk between GFP and optogenetic 
tools used for optobody targeting of fluorescent proteins.
To expand the versatility of optobody to targeting of endogenous 
proteins, we generated an actin optobody, a β2AR optobody and a 
gelsolin (GSN) optobody, generated from nanobodies and a GCN4 
optobody, generated from a scFv (Supplementary Fig. 11).
We first converted the actin nanobody13 to an actin optobody. 
In darkness, the inactive actin optobody was dispersed in the cytosol 
of cells, but light stimulation induced activation of the actin optobody, 
resulting in its targeting to actin filaments (Fig. 2a, Supplementary 
Fig. 12b and Supplementary Video 4). Next, to generate a β2AR 
optobody, we engineered the nanobody, Nb60, which detects an 
inactive form of β2AR14. Light illumination triggered translocation 
of the activated β2AR optobody to the membrane, where it targeted 
inactive β2AR (Fig. 2b, Supplementary Fig. 12c and Supplementary 
Video 5). We then used a GSN nanobody (GSN Nb11) as a tem-
plate for a GSN optobody, which specifically recognizes the GSN G2 
domain15. On light stimulation, the mito-conjugated GSN optobody 
was activated and EGFP-GSN clearly moved toward the mitochon-
dria (Fig. 2c, Supplementary Fig. 12d and Supplementary Video 6). 
We further tested whether the split GSN nanobody fragments 
retained their specificity for the target protein after activation. 
Treatment with rapamycin to activate the split GSN nanobody did 
not induce translocation of the GSN G4–G6 domain; however, the 
GSN G1–G3 domain did bind to the activated split GSN nanobody 
(Supplementary Fig. 13). These results indicate that reassembled 
nanobody fragments retain a specificity of the original nanobody.
In addition to nanobodies, we applied the optobody platform 
to scFvGCN4 (ref. 16). When Magnet-conjugated variable heavy 
(VH) and light (VL) chain domains were expressed together, they 
spontaneously reassembled and bound to Mito-fused 24xGCN4 
peptides, even in darkness (Supplementary Fig. 14b,c). Thus, we 
generated two pairs of scFvGCN4 fragments by splitting each vari-
able domain as described for generation of the optobody (Fig. 2d 
and Supplementary Fig. 14a). The split fragments of scFvGCN4 
VH domain accumulated at mitochondria on light stimulation 
(Fig. 2e–g, Supplementary Fig. 12e and Supplementary Video 7), 
whereas the split fragments of scFvGCN4 VL domain showed no 
targeting of mitochondria (Supplementary Fig. 14d,e). These results 
demonstrate that the activity of scFvGCN4 can also be adapted to 
the optobody system, but only the VH domain of scFv is suitable for 
this purpose.
We next assessed the suitability of GSN and β2AR optobodies 
as new tools for optogenetic inhibition on their endogenous target 
proteins. To investigate light-induced perturbation of GSN func-
tion by GSN optobody, we monitored migration of NIH3T3 cells 
expressing a GSN optobody, with or without light stimulation. Cells 
illuminated with blue light explored a more restricted territory than 
cells in darkness, exhibiting a considerable decrease in migration 
distance and instantaneous speed (Fig. 3a–c). Chemical-induced 
activation of split GSN nanobody fragments also led to inhibitory 
effects on cell movement (Supplementary Fig. 15). Spatiotemporal 
activation of GSN optobody recruited GSN protein at the subcel-
lular level, showing that local stimulation of the GSN optobody in 
a specifically targeted cell induced a spatially controlled defect in 
cell migration (Supplementary Fig. 16). This capability provides an 
opportunity for optically modulating endogenous GSN in a spatio-
temporal manner.
Next, to examine the ability of β2AR optobody to inhibit endog-
enous β2AR, we photo-stimulated human embryonic kidney 293 
(HEK293) cells expressing β2AR optobody and monitored down-
stream β2AR signaling14. Activation of β2AR with isoprenaline 
(ISO), resulting in β2AR internalization and cAMP-mediated Ca2+ 
influx, was blocked by the intact β2AR nanobody (Supplementary 
Figs. 17 and 18). In β2AR optobody-expressing cells, light illumi-
nation inhibited the internalization of β2AR-iRFP, significantly 
decreasing the relative internalization ratio to a degree comparable 
to that of the β2AR nanobody (Fig. 3d–f). The blue-light illumina-
tion of β2AR optobody-transfected cells also induced a decrease in 
Ca2+ influx into the cells, even with ISO treatment (Fig. 3g,h). These 
observations indicate that the activated β2AR optobody is capable 
of light-induced disruption of endogenous β2AR signaling.
In summary, we have developed an optogenetic platform, termed 
Optobody, for light-inducible regulation of intrabody activity and 
manipulation of endogenous target protein function. Although the 
representative intrabodies we developed showed a clear expression 
pattern in cells, intrabodies sometimes aggregate. Therefore, in 
choosing an intrabody as a backbone for optobody, it is important 
to consider the expression pattern of original intrabody inside cells. 
In addition, when some fragments of optobody such as C-terminal 
fragment of GFP optobody or N-terminal fragment of GCN4 opto-
body are highly expressed in cells, they have a self-aggregated ten-
dency before stimulation (Supplementary Fig. 19). Even though the 
aggregation did not contain its target protein, it is another point to 
be considered in the use of optobodies in cellular applications.
In this study, we used blue-light responsive photoreceptors for 
generating optobodies. However, the concept underlying the opto-
body is a split intrabody fragment and reassembly via an inducer, 
and is thus not limited to blue-light stimulation. We strongly believe 
that our technique could be applied to other inducible dimerization 
systems, including a near-infrared induced optobody. Furthermore, 
there are a variety of techniques that use antibody fragments, such 
as chimeric antigen receptor-T (CAR-T) cells. The optobody might 
thus be applied to engineering of conventional antibody techniques 
to convert these tools to inducible antibody-activated systems, sug-
gesting a broader drug-activating concept.
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Methods
Plasmid construction. Individual optobody plasmids were generated using 
Gibson Assembly Cloning (NEB). All complementary DNA encoding optobody 
fragments were regulated by CMV promoter. Sequences encoding the GFP 
nanobody from pcDNA3_NSlmb-vhhGFP4 (Addgene, plasmid 35579) were used 
as a template for split GFP nanobody fragments. To create FRB–FKBP-conjugated 
split GFP nanobodies on a single expression plasmid, we first generated a vector 
containing FRB-mCherry-P2A-FKBP. Enhanced green fluorescent protain 
(EGFP) in pEGFP-C1 (Clontech) between AgeI and BspEI sites was then replaced 
with PCR-amplified FRB-mCherry and P2A-FKBP sequences. Sequences of 
split GFP nanobody fragments (N-terminal fragments, residues 1–44, 1–65 and 
1–90; C-terminal fragments, residues 45–117, 65–117 and 91–117) were PCR-
amplified to contain glycine-serine linkers (GGGGS)x2 positioned immediately 
adjacent to the cleavage residue. PCR products encoding split GFP nanobody 
fragments and FRB-mCherry-P2A-FKBP were co-inserted into pEGFP-C1 
(Clontech) after removing EGFP by digesting with AfeI and BspEI. nMagHigh1 
and pMagHigh1, used for generating the GFP optobody, were synthesized by 
Cosmo Genetech. Sequences of the split GFP nanobody N-terminal fragment 
(residues 1–65) containing (GGGGS)x3 and nMagHigh1 were PCR-amplified 
and inserted into piRFP682-C1 at an EcoRI site. PCR-amplified sequences 
encoding the split GFP nanobody C-terminal fragment (residues 66–117) and 
pMagHigh1 (in different orientations) were cloned into pFusionRed-C1. The two 
sequences encoding the GFP nanobody C-terminal fragment and pMagHigh1 
were connected by (GGGGS)x3 linkers. Expression plasmids for C24A and 
C24S mutant GFP nanobodies were generated by mutagenizing sequences 
encoding the N-terminal fragment of the GFP nanobody by PCR-driven overlap 
extension using mutagenic oligonucleotides. The resulting PCR-amplified 
sequences encoding mutant GFP nanobodies were inserted into pmCherry-N1 
(Clontech). The C24S mutant GFP optobody was created by co-inserting PCR 
products encoding the C24S mutant GFP nanobody N-terminal fragment and 
nMagHigh1 into piRFP682-C1 at the EcoRI site. GFP optobody conjugated with 
the photoreceptor proteins, pMag and pMagFast1, were constructed by PCR-
amplification followed by insertion with the GFP nanobody C-terminal fragment 
into pFusionRed-C1. PCR-amplified sequences encoding SspB (R73Q) or iLID 
were cloned into piRFP682-C1 or pFusionRed-C1 together with an N-terminal 
or C-terminal fragment of the GFP nanobody, respectively. The Tom20-GFP 
vector was constructed by excising a PCR product encoding Tom20 (residues 
1–33) by digesting with EcoRI and BamHI, followed by insertion into pEGFP-N1 
(Clontech). Sequences encoding H2B, Giantin (residues 9391–9777) and KRAS 
tail (residues 502–561) were PCR-amplified and inserted into the pEGFP-C1 
vector (Clontech) at EcoRI and BamHI sites.
The PA-deGraFP components NSlmb and NSnoFbox were generated using 
pcDNA3_NSlmb-vhhGFP4 (Addgene, plasmid 35579) and pcDNA3_NSnoFbox-
vhhGFP4 (Addgene, plasmid 35580), respectively, as templates. PCR-amplified 
NSlmb-vhhGFP4 and NSnoFbox-vhhGFP4 were inserted into pFusionRed-N1 
at NheI and EcoRI sites. PCR-amplified NSlmb was inserted into the previously 
generated GFP optobody vector containing an N-terminal or C-terminal fragment 
of the GFP nanobody at NheI/AgeI and NheI/XhoI sites, respectively.
The protein sequences of the GFP nanobody, mCherry nanobody, actin 
nanobody, GSN nanobody, β2AR nanobody and scFvGCN4 VH domain were 
aligned using the T-Coffee Multiple sequence alignment program, and each split 
site of the intrabodies was selected. The actin optobody vector was constructed 
using an actin nanobody (Chromotek) as a template. PCR products encoding 
the actin nanobody N-terminal fragment (residues 1–64), C-terminal fragment 
(residues 65–168), (GGGGS)x3-nMagHigh1 and pMagHigh1-(GGGGS)x3 
were PCR-amplified. The actin nanobody N-terminal fragment and (GGGGS)
x3-nMagHigh1 pair was inserted into pmCherry-C1 (Clontech) at the AgeI site, 
and the pMagHigh1-(GGGGS)x3 and C-terminal actin nanobody fragment pair 
was cloned into piRFP682-C1 at the BspEI site.
The mCherry optobody was generated by PCR-amplified sequences encoding 
the N-terminal fragment (residues 1–65) and C-terminal fragment (residues 
66–129) of the mCherry nanobody. The amplified fragments were cloned with 
(GGGGS)x3-nMagHigh1 and pMagHigh1-(GGGGS)x3 into piRFP682-C1 and 
pmEGFP-N1, respectively, at the EcoRI site.
The GSN optobody was created by PCR-amplifying sequences encoding the 
N-terminal fragment (residues 1–65) and C-terminal fragment (residues 66–129) 
of the GSN nanobody (provided by J. Gettemans, Ghent University, Belgium). 
The resulting fragments were cloned together with (GGGGS)x3-nMagHigh1 and 
pMagHigh1-(GGGGS)x3 into pFusionRed-N1 and piRFP682-C1, respectively, 
at the EcoRI site. The FRB–FKBP-conjugated split GSN nanobody was generated 
according to the GSN optobody process by replacing the dimerization domains 
with FRB and FKBP. The C-terminal fragment of the split GSN nanobody was 
conjugated to mitochondria by inserting a PCR product encoding monoamine 
oxidase A (residues 490–527) into the ppMagHigh1-GSN nanobody C-terminal 
fragment-FusionRed and pFKBP-GSN nanobody C-terminal fragment-FusionRed 
at BsrGI and NotI sites. The human GSN sequence was PCR-amplified from GSN-
bio-His (Addgene, 52067) and inserted into pEGFP-C1 (Clontech) at the EcoRI 
site. The PCR-amplified sequence encoding GSN (G2–3) or GSN (G4–6) was also 
cloned into pEGFP-C1 (Clontech) at the EcoRI site.
scFvGCN4 sequences from pHRdSV40-scFv-GCN4-sfGFP-VP64-GB1-NLS 
(Addgene, plasmid 60904) were used as a template for the GCN4 optobody. The 
GCN4 optobody was generated by PCR-amplifying sequences encoding scFvGCN4 
VL-VH N-terminal fragment (residues 1–196), scFvGCN4 VH C-terminal 
fragment (197–247), (GGGGS)x3-nMagHigh1 and pMagHigh1-(GGGGS)
x3, and then cloning the scFvGCN4 VL-VH N-terminal fragment-(GGGGS)
x3-nMagHigh1 and pMagHigh1-(GGGGS)x3-scFvGCN4 VH C-terminal fragment 
into pFusionRed-N1 and piRFP682-C1, respectively, at the EcoRI site. In the case 
of splitting the VL domain of scFvGCN4, sequences encoding the scFvGCN4 
VL N-terminal fragment (residues 1–64) and scFvGCN4 VL C-terminal-VH 
fragment (residues 65–247) were PCR-amplified and cloned as described for the 
GCN4 optobody cloning process. scFvGCN4 VH conjugated with (GGGGS)
x3-nMagHigh1 and scFvGCN4 VL conjugated with pMagHigh1-(GGGGS)x3 also 
were generated in the same manner. A vector encoding Mito-conjugated 24xGCN4 
peptides was created from pcDNA4TO-Mito-mCherry-24xGCN4_v1 (Addgene, 
plasmid 60913) by replacing mCherry with EGFP at EcoRI and NotI sites.
The β2AR optobody was generated from the β2AR nanobody (synthesized 
by Genescript) and PCR-amplified sequences encoding N-terminal (residues 
1–65) and C-terminal (residues 66–117) fragments of the β2AR nanobody. The 
resulting fragments were PCR-amplified together with (GGGGS)x3-nMagHigh1 
and pMagHigh1-(GGGGS)x3, respectively. A single vector expressing β2AR 
optobody was generated by connecting the β2AR nanobody N-terminal fragment-
(GGGGS)x3-nMagHigh1 and pMagHigh1-(GGGGS)x3- β2AR nanobody 
C-terminal fragment with a tension linker and inserting the resulting product into 
pFusionRed-N1 at AgeI and BamHI sites. The β2AR-iRFP682 expression vector 
was created by cloning cDNA encoding human β2AR into piRFP682-N1 at the 
EcoRI site. A plasmid encoding Cnga2(C460W/E583M)-EGFP was constructed by 
inserting cDNA encoding mouse Cnga2 into pEGFP-N1 at the EcoRI site. PCR-
amplified Cnga2 containing a C460W mutation was cloned, after which a Cnga2 
sequence containing C460W and E583M mutations was cloned into pEGFP-C1 at 
the EcoRI site.
Cell culture and transfection. HeLa, NIH3T3 and HEK293 (ATCC) cells were 
maintained in Dulbecco’s Modified Eagle’s Medium (Gibco) supplemented with 
10% fetal bovine serum (Invitrogen) at 37 °C in a humidified 10% CO2 atmosphere. 
Cells were tested using an e-Myco Mycoplasma PCR detection kit (iNtRON) and 
confirmed to be free from mycoplasma.
cDNA encoding each optobody N-terminal and C-terminal fragment was 
transfected at a 1:1 ratio. For monitoring migration of NIH3T3 cells, NIH3T3 
cells were plated on a 96-well plate pre-coated with 5 μg ml−1 fibronectin. For 
imaging, HEK293 cells were plated on a 96-well plate pre-coated with poly-d-lysine 
and then transfected using either a jetPrime (Polyplus) or Microporator (Neon 
Transfection System, Invitrogen), according to the manufacturers’ instructions. 
Electroporation conditions were additionally optimized to increase transfection 
efficiency for HeLa cells (two pulses of 980 V for 35 ms) and NIH3T3 cells (three 
pulses of 1,450 V for 10 ms).
Protein production of recombinant GFP and anti-GFP nanobody variants. 
DNA fragments encoding EGFP was inserted to pJAhX vector plasmid (home-
made) to obtain the protein fused to a poly-histidine (His10) tag at its N terminus. 
The modified plasmid was transformed into Escherichia coli BL21(DE3) RIPL 
strain (Novagen). Expression of the protein was induced by the addition of 0.1 mM 
isopropyl-β-d-thio-galactoside (IPTG) at 18 °C when the bacteria grew to an optical 
density (OD600) of 0.6 in LB medium. Bacterial cell lysate with overexpressed His10-
EGFP was prepared by sonication in Buffer A (20 mM Tris-HCl pH 7.5, 100 mM 
NaCl and 1 mM NaN3). The supernatants of each sample were applied to gravity 
flow columns filled with HisPur cobalt resin (Thermo Scientific). Resin-bound 
His10-EGFP was washed with 3 column volumes of 10 mM imidazole-added Buffer 
A, and eluted with 200 mM imidazole-added Buffer A. Eluted sample was further 
purified with a HiTrapQ HP anion exchange column (GE Healthcare). For size-
exclusion chromatography, the unbound fractions from HiTrapQ HP were collected 
and loaded onto a HiLoad 26/60 Superdex 75 gel filtration column (GE Healthcare). 
Purified His10-EGFP was concentrated by using an Amicon Ultra 10K (Millipore).
PCR products of GFP nanobody, GFP nanobody N65-FRB and FKBP-GFP 
nanobody C66 were individually inserted into pJKXCPDh plasmids (home-made) 
to express proteins fused to His10-tagged CPD (cysteine protease domain) at their 
C terminus. The strain, culture condition and induction condition of E. coli were 
same in the case of EGFP. Bacterial cell lysate with overexpressed GFP nanobody, 
GFP nanobody N65-FRB or FKBP-GFP nanobody C66 were individually prepared 
by sonication in Buffer A. The supernatants of each sample were applied to gravity 
flow columns filled with HisPur cobalt resin (Thermo Scientific). To remove the 
CPD-His10 tag and elute the protein from cobalt resin, resin-bound GFP nanobody, 
GFP nanobody N65-FRB and FKBP-GFP nanobody C66 were treated with 
Buffer A containing 0.1 mM phytate for 2 h and eluted. Further purification and 
concentration steps were same in the case of EGFP.
To obtain rapamycin-engaged GFP nanobody N65-FRB and FKBP-GFP 
nanobody C66 heterodimer, the PCR product of GFP nanobody N65-FRB 
was inserted into pJAX vector (home-made). The modified plasmid was 
co-transformed with FKBP-GFP nanobody C66 pJKXCPDh into BL21(DE3) RIPL.
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(v.1.50b, US National Institutes of Health; http://imagej.nih.gov/ij/), or MATLAB 
software (v.R2015a, Mathworks). Colocalization of two molecules in different 
fluorescence colors was quantitatively analyzed with Pearson’s correlation 
coefficient using custom MATLAB scripts (available in the Supplementary Code 
file). The intensity pattern along a line was measured with the Plot Profile tool in 
ImageJ software. The degradation of EGFP-H2B and changes in the fluorescence 
intensity of R-GECO were analyzed by measuring fluorescence intensity at 
designated regions of interest using the Annotations and Measurements tool or 
Time Measurement tool. Cell migration tracking data were produced using the 
MTrackJ plugin in ImageJ software, and analyzed using programs described in the 
protocol17. Migration tracks were displayed using the Plot_At_Origin program. 
Migration distance and instantaneous speed were calculated using the Speed 
program. For analysis of β2AR internalization, the shape of the entire cell and 
internalized portion were drawn using Polygon selection in ImageJ software. The 
fluorescence intensity of the selected region was recorded using the ROI manager 
in ImageJ software, and internalized receptors were calculated through inside 
fluorescence intensity/total fluorescence intensity18. Statistical significance was 
evaluated using a two-tailed Student’s t-test.
Statistics and reproducibility. The experiments in Figs. 1b,f,g, 2a–c,e–g and 3a–h, 
Supplementary Figs. 1d,e, 3b,c, 5a–d, 6a–d, 7a,b,d,e, 8b–d, 9c ,d, 10a–d, 11a–d, 
12a–e, 13a–c, 14b–e, 15a–c, 16a–d, 17a–d, 18a–c and 19a–d and Supplementary 
Videos 1–7 were repeated with multiple independent experiments (at least three 
times) originating from independent cell culture. Each experiment produced 
similar results. The affinity in Supplementary Fig. 3 were once measured with the 
purified protein in one experiment. The detailed value of BLI results is provided in 
Supplementary Note 1. The co-immunoprecipitation assay in Supplementary Fig. 4 
was performed four times originating from independent cell preparation, resulting 
in similar data to the western blot.
The n value in figure legends represents the number of cells imaged  
per condition. For quantification and statistical significance test, data is  
displayed as combined graphs from multiple experiments and applied by a  
two-tailed Student’s t-test. Before the Student’s t-test, an F-test was performed  
to compare variances.
The statistical information for each figure is described below.
Figure 1b from top to bottom: n = 8, split site 44/45; n = 8, split site 
65/66; n = 10, split site 90/91; P values: split site 44/45 versus 65/66 at +Rap, 
P = 4.58 × 10−5; split site 65/66 versus 90/91 at +Rap, P = 7.06 × 10−4 by Student’s 
two-tailed t-test.
Figure 3b,c: FuRed, n = 205; GSN nanobody, n = 132; GSN optobody, n = 136. 
Figure 3b: P values: FuRed versus GSN optobody at 0 h, P = 0.0538; GSN nanobody 
versus GSN optobody at 2 h, P = 0.0035 by Student’s two-tailed t-test. Figure 3c:  
P values: GSN optobody −Light versus +Light, P = 7.89 × 10−4; GSN nanobody 
versus GSN optobody at +Light, P = 0.8994 by Student’s two-tailed t-test.
Figure 3e,f: n = 37, FuRed; n = 23, β2AR nanobody; n = 44, β2AR nanobody –
Light; n = 37, β2AR nanobody +Light. Figure 3e: P values: β2AR nanobody –Light 
versus +Light, P = 0.0571 by Student’s two-tailed t-test. Figure 3f: P values: β2AR 
nanobody versus β2AR optobody, P = 0.6046; β2AR nanobody –Light versus 
+Light, P = 8.62 × 10−9 by Student’s two-tailed t-test.
Figure 3h: n = 67, iRFP; n = 51, β2AR nanobody; n = 62, β2AR nanobody –
Light; n = 50, β2AR nanobody +Light; P values: β2AR nanobody –Light versus 
+Light, P = 6.06 × 10−5 by Student’s two-tailed t-test
Reporting Summary. Further information on research design is available in the 
Nature Research Reporting Summary linked to this article.
Data availability
The data supporting the findings of this study are available within the paper and its 
Supplementary Information files. Extra data are available from the corresponding 
author upon reasonable request.
Code availability
The code for high-throughput analysis of two-channel time-lapse colocalization in 
individual cells are available in Supplementary code files.
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Expression of the protein was induced by the addition of 0.1 mM IPTG at 
18 °C when the bacteria grow to an OD600 of 0.6 in LB. At the same time, 10 μM 
of rapamycin was also treated to induce FKBP–FRB dimerization. The protein 
purification and concentration steps were same in the case of GFP nanobody  
N65-FRB or FKBP-GFP nanobody C66.
BLI measurement. To obtain kinetic parameters of protein–protein interaction 
including a KD value of EGFP and GFP nanobody, BLI measurement was 
performed using the BLItz instrument (ForteBio). A 4 µl volume of His10-EGFP 
(4 mg ml−1) was loaded onto a nickel-nitrilotriacetic acid (Ni-NTA) biosensor for 
120 s. The baseline was determined by incubating the sensor with 400 μl Buffer A 
for 30 s. To measure protein association until reaching a steady state, 4 µl volume 
of GFP nanobody was used. The binding was used to measure protein dissociation 
(for a duration of 180 s). After repeated BLI measurements in more than three 
different concentrations of GFP nanobody, the binding kinetics between EGFP 
and GFP nanobodies was deduced by using BLItz Pro software (ForteBio). Binding 
kinetics between EGFP and GFP nanobody N65-FRB, FKBP-GFP nanobody C66 
or rapamycin-engaged GFP nanobody N65-FRB, FKBP-GFP nanobody C66 were 
measured using the same process as for the GFP nanobody. Additional data from 
the process is provided in Supplementary Note 1.
Co-immunoprecipitation assay and western blot. Hela cells were transfected with 
sequence motif DYKDDDDK (FLAG)-GFP nanobody-iRFP, FLAG-iRFP-GFP 
nanobody N65-nMagHigh1, FLAG-pMagHigh1-GFP nanobody C66-FuRed or both 
FLAG-iRFP-GFP nanobody N65-nMagHigh1 and Myc-pMagHigh1-GFP nanobody 
C66-FuRed with human influenza hemagglutinin (HA)-tagged GFP by using 
jetPrime (Polyplus). At 4 h after transfection, cells were illuminated with blue LEDs 
(Photron) for 24 h. Cells were collected and cell extracts were prepared with Pierce 
immunoprecipitation lysis buffer (Thermo Scientific) containing Halt protease 
inhibitor cocktail (Thermo Scientific). Lysates were incubated with Monoclonal 
anti-FLAG M2 antibody (Sigma) overnight at 4 °C on a rocking platform. Protein 
A/G PLUS-Agarose (Santa Cruz) was added to the mixture for 2 h at 4 °C while 
rotating. And then the beads were collected by centrifugation, washed in lysis buffer 
and resuspended in SDS gel loading buffer. The proteins were separated on Bolt 
4–12% Bis-Tris Plus Gels, transferred to a polyvinylidene difluoride membrane 
using iBlot Transfer Stack (Gibco) and detected by immunoblotting.
Membranes were blocked with TBS/Odyssey blocking buffer and stained with 
Rabbit anti-HA (Cell Signaling), Rabbit anti-FLAG (Cell signaling), Rabbit anti-
Myc (Abcam) and Mouse anti-GAPDH (Thermo Scientific) overnight at 4 °C with 
shaking. After washing with TBST three times, the membranes were stained with 
IRDye 680RD Goat anti-Rabbit immunoglobulin G (IgG) (heavy + light chains; 
H+L) and IRDye 800CW Goat anti-Mouse IgG (H+L) (LI-COR) for 1 h at room 
temperature. After washing with TBST three times, the membrane were imaged 
with LI-COR Odyssey using the Image Studio software.
Live-cell imaging and photoactivation. For imaging, all cells were plated on 96-well 
plates (μ-Plate 96-well ibiTreat, ibidi GmbH). Live-cell imaging was performed using 
a Nikon A1R confocal microscope (Nikon Instruments) mounted onto a Nikon 
Eclipse Ti body equipped with a Nikon CFI Plan Apochromat VC objective (×60/1.4 
numerical aperture, Nikon Instruments) and an ImageXpress Micro XLS automated 
epifluorescence microscope (Molecular Devices) equipped with a ×10 Plan Fluor 
objective and a 4.66 megapixel CMOS camera with a 16-bit readout. A Chamlide TC 
system placed on a Nikon A2R confocal microscope stage was used for maintaining 
environmental conditions at 37 °C and 10% CO2 (Live Cell Instruments).
For cells imaged using the Nikon A1R confocal microscope (Nikon 
Instruments), photoactivation was conducted using a 488-nm laser emitted 
through a Galvano scanner, incorporated in a hybrid confocal scan head with 
a high-speed hyper selector (Nikon). The shape and size of the photoactivated 
region were adjusted using Nikon imaging software (NIS-elements). A laser power 
density of 490 μW mm−2 (measured with an ADCMT optical power meter) was 
used for photoexcitation. Photoactivation was also delivered with 96 blue LEDs 
(Photron) mounted on a customized array (Live Cell Instruments) that provided 
a peak emission of 470 nm with 250 μW mm−2 (measured with an ADCMT 
optical power meter). For imaging cells on the ImageXpress Micro XLS automated 
epifluorescence microscope (Molecular Devices), the excitation light was produced 
with an excitation filter for GFP (GFP-3035D-NTE-ZERO, Semrock). A light 
intensity of 40 μW mm−2 was used for photoactivation.
Image processing and analysis. Images were analyzed using Nikon imaging 
software (NIS-elements AR 64-bit v.3.21, Laboratory Imaging), ImageJ software 
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